Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model

Frontiers in Medicine

Nolwenn Fichou¹ 

关键词: lutetium-177;    bismuth-213;    multiple myeloma;    CD138;    radioimmunotherapy;   

DOI  :  10.3389/fmed.2015.00076

学科分类：医学（综合）

来源: Frontiers

【 摘 要 】

ObjectivesRadioimmunotherapy (RIT) has emerged as a potential treatment option for multiple myeloma (MM). In humans, a dosimetry study recently showed the relevance of RIT using an antibody targeting the CD138 antigen. The therapeutic efficacy of RIT using an anti-CD138 antibody coupled to 213Bi, an α-emitter, was also demonstrated in a preclinical MM model. Since then, RIT with β-emitters has shown efficacy in treating hematologic cancer. In this paper, we investigate the therapeutic efficacy of RIT in the 5T33 murine MM model using a new anti-CD138 monoclonal antibody labeled either with 213Bi for α-RIT or 177Lu for β-RIT.

【 授权许可】

CC BY